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1. INTRODUCTION {#jcmm13595-sec-0001}
===============

Despite widespread screening programs, cervical cancer remains frequent cancer among women worldwide, with the highest mortality rates in developing countries.[1](#jcmm13595-bib-0001){ref-type="ref"} Although human papillomavirus (HPV) vaccines are available, cervical cancer still causes a considerable amount of death because of the limited application of the vaccine. Persistent infection with high‐risk HPV is the main aetiological factor in cervical carcinogenesis.[2](#jcmm13595-bib-0002){ref-type="ref"}, [3](#jcmm13595-bib-0003){ref-type="ref"}, [4](#jcmm13595-bib-0004){ref-type="ref"} However, HPV infection alone does not sufficiently explain the occurrence of cervical cancer because HPV oncogenes E6 and E7 can immortalize but do not transform human epithelial cells.[5](#jcmm13595-bib-0005){ref-type="ref"}, [6](#jcmm13595-bib-0006){ref-type="ref"} Thus, HPV infection can be considered an initial hit in the multistep carcinogenesis that leads to cervical cancer, and additional factors are involved in the progression of HPV‐infected lesions to cancer.[7](#jcmm13595-bib-0007){ref-type="ref"} The changes in level of some cellular proteins that are crucial regulators in some molecular signalling pathways, as the second hit, might be implicated in this tumorigenic model.

Inositol polyphosphate 4‐phosphatase type II (INPP4B) is a phosphoinositide phosphatase that dephosphorylates PI(3,4)P2 to PI(3)P. Interaction of PI(3,4)P2 with the pleckstrin homology (PH) domain of AKT is required for dimerization and full activation of AKT,[8](#jcmm13595-bib-0008){ref-type="ref"} so like phosphatase and tensin homolog (PTEN), INPP4B may act as a tumour suppressor by antagonizing the PI3K/AKT signalling pathway.[9](#jcmm13595-bib-0009){ref-type="ref"} However, recent reports demonstrated the controversial role of INPP4B in carcinogenesis in various tumours. INPP4B level was lower in follicular‐like thyroid cancer tissues, melanocytic neoplasm, prostate cancer and breast cancer than in corresponding normal tissues, and knock‐down of INPP4B activated AKT and increased the migratory, invasive and proliferative capacity in these cancer cells.[9](#jcmm13595-bib-0009){ref-type="ref"}, [10](#jcmm13595-bib-0010){ref-type="ref"}, [11](#jcmm13595-bib-0011){ref-type="ref"}, [12](#jcmm13595-bib-0012){ref-type="ref"} In contrast, INPP4B was found as an oncogenic regulator in colon cancer, acute myeloid leukaemia and in a subset of melanomas.[13](#jcmm13595-bib-0013){ref-type="ref"}, [14](#jcmm13595-bib-0014){ref-type="ref"}, [15](#jcmm13595-bib-0015){ref-type="ref"} INPP4B promoted cell proliferation and chemical resistance in these cancer cells, mainly by activating serum‐ and glucocorticoid‐regulated kinase 3 (SGK3).[13](#jcmm13595-bib-0013){ref-type="ref"}, [15](#jcmm13595-bib-0015){ref-type="ref"} Therefore, the role of INPP4B needs to be explored in other cancer models for an overall picture of its function.

Our previous study demonstrated liver kinase B1 (LKB1) as an important tumour suppressor in cervical cancer. Overexpression of LKB1 inhibited HeLa cell proliferation and activated the AMPK pathway.[16](#jcmm13595-bib-0016){ref-type="ref"} More importantly, overexpression of LKB1 up‐regulated INPP4B and reduced p‐AKT level, which suggested that LKB1 is involved in negative regulation of the PI3K/AKT pathway by INPP4B.

In this study, we further assessed the function of INPP4B in cervical cancer. INPP4B was overexpressed in cervical cancer cells to explore the role of INPP4B in cell proliferation and metastasis. Our findings confirmed INPP4B as a tumour suppressor in cervical cancer by regulating AKT and SGK3 activities in various cervical cancer cell lines.

2. MATERIALS AND METHODS {#jcmm13595-sec-0002}
========================

2.1. Cell lines {#jcmm13595-sec-0003}
---------------

Cervical cancer cell lines HeLa, SiHa and C33a from the American Type Culture Collection (Manassas, Va) were maintained in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% foetal calf serum (Invitrogen), 100 IU/mL penicillin and 100 μg/mL streptomycin (Sigma, St. Louis, MO). CaSki cells were maintained in RPMI1640 (Invitrogen, Carlsbad, CA) supplemented with 10% foetal calf serum (Invitrogen). Cells were passaged every 2 days with 0.25% trypsin (Invitrogen).

2.2. Plasmids and viral infection {#jcmm13595-sec-0004}
---------------------------------

INPP4B complementary DNA was cloned into a lentiviral vector GV367, and lentivirus carrying GV367‐INPP4B or empty vector was packaged by Genechem Co. (Shanghai). Purified lentivirus was used to infect cultured cervical cancer cells in the presence of 5 μg/mL Polybrene (Genechem, China) according to the technical manual. At 72 hour after infection, stable clones were selected with 2 μg/mL puromycin (Thermo Fisher).

2.3. Small interfering RNA and transfection {#jcmm13595-sec-0005}
-------------------------------------------

CaSki cells were seeded in 6‐well plates at 4 × 10^5^ cells per well and cultured in medium without antibiotics for 24 hour. INPP4B‐specific siRNA (RiboBio, China) or negative control (NC) was transfected into cells with use of Lipofectamine 2000 (Invitrogen) according to the manufacturer\'s instructions.

2.4. RNA extraction, cDNA synthesis and real‐time PCR {#jcmm13595-sec-0006}
-----------------------------------------------------

Total RNA in tissue specimens was extracted using TRIzol reagent (Invitrogen) as the manufacturer recommended. Then, cDNA was synthesized with use of the PrimeScript RT reagent kit with gDNA Eraser (Takara, Shiga, Japan) as the manufacturer recommended. The primers were for INPP4B, 5′‐GCCGACCACATCACCACAG‐3′(forward) and 5′‐ TTTCCGCTCACACTTTCCG‐3′(reverse); β‐actin, 5′‐CCATATGCTCACTCAGATGATGT‐3′(forward) and 5′‐GTGTATCATCTCCACAGAGAGTT‐3′ (reverse). Real‐time PCR involved use of SYBR Premix Ex Taq (Takara) following the manufacturer\'s instructions in the CFX96 Touch Real‐Time PCR Detection System (Bio‐Rad, USA).

2.5. Western blot assay {#jcmm13595-sec-0007}
-----------------------

Total protein was extracted from cell lines using RIPA Lysis Buffer (Beyotime Biotechnology, China) as the manufacturer recommended and measured using Pierce BCA Protein Assay Kit (Thermo Fisher, Massachusetts). Western blot assay was performed as described[17](#jcmm13595-bib-0017){ref-type="ref"} with specific antibodies for INPP4B (1:1000), PTEN (1:1000), AKT (1:1000) and phospho‐AKT (Ser473, 1:2000, all Cell Signaling Technology); SGK3 (1:1000, Santa Cruz Biotechnology); phospho‐SGK3 (Thr320, 1:1000), mammalian target of rapamycin (mTOR; 1:1000), phospho‐mTOR (1:1000) and phospho‐p70S6k (1:1000, all Cell Signaling Technology); and Phosphoinositide‐dependent kinase‐1 (PDK1; 1:1000) and GAPDH (1:3000, Proteintech, China). GAPDH was a loading control.

2.6. Cell proliferation, colony formation and anchorage‐independent growth assays {#jcmm13595-sec-0008}
---------------------------------------------------------------------------------

For cell proliferation assay, cells were seeded onto 96‐well plates at 3 × 10^3^ cells per well. Cell proliferation was determined by use of the Cell Counting Kit‐8 (CCK‐8) (Dojindo, Japan) as the manufacturer recommended. For colony formation assay, cells were cultured on 6‐well plates at 500 cells per well for 10‐14 days, and then colonies were counted after fixing and staining with methyl alcohol and 0.5% crystal violet solution, respectively. Anchorage‐independent growth assays were performed as described.[17](#jcmm13595-bib-0017){ref-type="ref"}

2.7. Cell migration and invasion assays {#jcmm13595-sec-0009}
---------------------------------------

Transwell inserts (8 μm, 24‐well format; Corning) and Matrigel (BD Bioscience)‐coated Transwell inserts were used to measure cell migration and invasion. In total, 2 × 10^4^ cervical cancer cells in 0.2 mL serum‐free medium were added in the upper chamber of 24‐well plates, with 0.6 mL DMEM containing 20% foetal bovine serum added to the lower chamber. After incubation for 24 to 48 hour, non‐invading cells were removed with use of a cotton swab, and the remaining cells were fixed, stained with 0.5% crystal violet solution and photographed in 5 random fields under a microscope.

2.8. Xenograft tumour growth assay {#jcmm13595-sec-0010}
----------------------------------

All procedures involving mice were approved by the Institutional Animal Care and Use Committee of Shandong University. A total of 1 × 10^7^ cells were suspended in 200 μL phosphate‐buffered saline and injected subcutaneously into the armpit of 5‐ to 6‐week‐old female BALB/c nu/nu mice (Vital River Laboratories, Beijing). After 2 weeks, tumours were measured using a vernier caliper twice a week for 6 weeks. Tumour volumes were calculated as *V* (mm^3^) = 0.5 × ab^2^. At the end of the assay, green fluorescent protein (GFP; carried by the lentiviral vector GV367) was measured in images from live mice by use of the In‐vivo Imaging System Kodak 2000 imager (Kodak). Then, mice were killed by cervical dislocation under sodium pentobarbital (50 mg/kg) anaesthesia, and tumours were excised and weighed.

2.9. Patients and tissue samples {#jcmm13595-sec-0011}
--------------------------------

Ethics approval was obtained from the Institutional Research Ethics Committee of Shandong University for all human tissues, cognate clinicopathological data and the experimental protocol used in this study. We used 45 quick‐frozen samples (25 squamous cell cervical cancer tissues and 20 normal cervical tissues) for mRNA extraction and real‐time PCR as well as 217 paraffin‐embedded tissue blocks (100 squamous carcinoma of the cervix, 49 cervical adenocarcinoma and 68 normal cervical tissues) for immunohistochemistry staining. All samples were collected from Qilu Hospital of Shandong University. Normal cervical tissues were from patients with chronic cervicitis or uterine fibroids who had undergone total hysterectomy. Patient consent was obtained for use of the tissue. Diagnosis was based on the World Health Organization Classification of Tumors.

2.10. Immunohistochemistry (IHC) {#jcmm13595-sec-0012}
--------------------------------

IHC involved the streptavidin‐peroxidase‐biotin IHC method according to standard procedures as we previously described.[17](#jcmm13595-bib-0017){ref-type="ref"} Slides were incubated with primary antibody for INPP4B (1:150; Cell Signaling) overnight at 4°C. All stained slides were observed by 2 independent investigators.

2.11. Statistical analysis {#jcmm13595-sec-0013}
--------------------------

Data are expressed as mean ± SEM. INPP4B mRNA levels were compared by Student\'s *t* test. Clinicopathological characteristics of patients with cervical cancer and INPP4B status were assessed by Pearson chi‐square test. Foci formation, anchorage‐independent growth, cell proliferation and cell invasion were analysed by Student\'s *t* test and one‐way ANOVA. All analysis involved use of SPSS v22.0 (SPSS Inc., Chicago, IL). *P* \< .05 was considered statistically significant.

3. RESULTS {#jcmm13595-sec-0014}
==========

3.1. INPP4B restrains the growth of cervical cancer cells {#jcmm13595-sec-0015}
---------------------------------------------------------

Firstly, we detected INPP4B in several cervical cancer cell lines with breast cancer MCF‐7 cells used as a positive control. INPP4B was potently expressed in CaSki and Ms‐751 cells as shown by bands near 110 kDa and additional bands of \~85 kDa, which was previously reported in melanocytic cells,[10](#jcmm13595-bib-0010){ref-type="ref"} but was almost absent in HeLa, SiHa and C33a cells (Figure [1](#jcmm13595-fig-0001){ref-type="fig"}A). Then, we used HeLa, SiHa and C33a cells with stable expression of INPP4B by transfection of a lentivirus carrying the protein gene. On CCK‐8 assay, proliferation was less for the three cell lines with exogenous expression of INPP4B than control cells (Figure [1](#jcmm13595-fig-0001){ref-type="fig"}B, All *P* \< .01). As compared with controls, cells with stable INPP4B overexpression for 14 days showed significantly decreased colony formation: HeLa, 397.3 ± 17.48 vs 291 ± 17.62, *P* = .0128; SiHa, 391.0 ± 11.59 vs 280.3 ± 20.42, *P* = .0092; and C33a, 403.3 ± 21.67 vs 213.3 ± 9.21, *P* = .0013 (Figure [1](#jcmm13595-fig-0001){ref-type="fig"}C and D). Moreover, INPP4B expression reduced cell growth of cells in soft agar: HeLa, 170.7 ± 11.85 vs 86.33 ± 16.59, *P* = .0144; SiHa, 155.0 ± 17.04 vs 68.33 ± 15.06, *P* = .0189; and C33a, 172.3 ± 18.41 vs 52.0 ± 8.54, *P* = .0041 (Figure [1](#jcmm13595-fig-0001){ref-type="fig"}E and F).

![INPP4B overexpression impedes the growth and proliferation of cervical cancer cells. A, Western blot analysis of INPP4B protein level in several cervical cancer cells. B, CCK8 assay analysis of proliferation of cervical cancer cells (HeLa, SiHa and C33a) after transfection with INPP4B cDNA cloned into a lentiviral vector GV367 (GV367‐INPP4B) or empty vector (GV367). \**P* \< .05. C‐D, Colony formation assays of proliferation of cervical cancer cells (HeLa, SiHa and C33a in each column) after transfection of GV367‐INPP4B or empty vector GV367. \**P* \< .05. E‐F, Anchorage‐independent growth assay of proliferation of cervical cancer cells (HeLa, SiHa and C33a in each column) after transfection with GV367‐INPP4B or empty vector GV367. \**P* \< .05, \*\**P* \< .01. Data are mean ± SEM, n = 3](JCMM-22-2935-g001){#jcmm13595-fig-0001}

3.2. INPP4B impedes migration and invasion of cervical cancer cells {#jcmm13595-sec-0016}
-------------------------------------------------------------------

We further explored the role of INPP4B in the migration and invasion ability of cervical cancer cells by Transwell assay. Overexpression of INPP4B notably reduced the number of migrated cells as compared with controls: HeLa, 133.0 ± 14.22 vs 65.0 ± 5.57, *P* = .0112; SiHa, 299.7 ± 31.78 vs 173.7 ± 28.09, *P* = .0411; and C33a, 172.0 ± 10.79 vs 82.0 ± 12.22, *P* = .0053 (Figure [2](#jcmm13595-fig-0002){ref-type="fig"}A and B). Moreover, the number of invasive cells was decreased: HeLa, 79.67 ± 12.44 vs 32.0 ± 6.658; SiHa, 633.0 ± 47.61 vs 326.0 ± 82.44; C33a, 247.7 ± 26.60 vs 107.7 ± 27.44 (all *P* \< .05) (Figure [2](#jcmm13595-fig-0002){ref-type="fig"}C and D).

![INPP4B overexpression reduces the migration and invasion of cervical cancer cells. A‐B, Transwell assay of migration ability of cervical cancer cells (HeLa, SiHa and C33a in each column) after transfection with GV367‐INPP4B and empty vector GV367. \**P* \< .05. C‐D, Transwell invasion assay of invasion ability of INPP4B stably transfected cervical cancer cells (HeLa, SiHa and C33a in each column) and control cells. \**P* \< .05. Data are mean ± SEM, n = 3](JCMM-22-2935-g002){#jcmm13595-fig-0002}

3.3. INPP4B suppresses the phosphorylation of AKT and SGK3 {#jcmm13595-sec-0017}
----------------------------------------------------------

To understand the mechanisms by which INPP4B reduced the proliferation and invasion of cervical cancer cells, we analysed the expression and activation of several pivotal molecules in the PI3K/AKT pathway. Consistent with other studies, phospho‐AKT (Thr473) level was lower in HeLa, SiHa and C33a cells with INPP4B expression than controls (Figure [3](#jcmm13595-fig-0003){ref-type="fig"}A and C). Phospho‐SGK3 (Thr320) level was reduced in INPP4B‐expressing HeLa and SiHa cells (Figure [3](#jcmm13595-fig-0003){ref-type="fig"}A and C). This result does not agree with previous reports, which depicted INPP4B as a tumour promoter by activating SGK3.[13](#jcmm13595-bib-0013){ref-type="ref"}, [15](#jcmm13595-bib-0015){ref-type="ref"} Considering that the activation of SGK3 and AKT mainly depends on their upstream molecule PDK1, we measured the levels of PDK1 and several downstream molecules of AKT/SGK3. Molecules downstream of AKT/SGK3, including mTOR/phospho‐mTOR and phospho‐p70S6K, were reduced in INPP4B‐expressing HeLa and SiHa cells (Figure [3](#jcmm13595-fig-0003){ref-type="fig"}B and D) as was the expression of the upstream molecule PDK1.

![INPP4B suppresses the phosphorylation of AKT and SGK3 in cervical cancer cells. A, Western blot assay of phosphorylation of AKT and SGK3 in cervical cancer cells (HeLa, SiHa and C33a) after transfection with GV367‐INPP4B or empty vector GV367. GAPDH was the loading control. B, Western blot assay of protein expression of PDK1 and several downstream molecules of AKT/SGK3. GAPDH was the loading control. C‐D Quantification of protein expression. Data are mean ± SEM, n = 3; \**P \<* .05, \*\**P* \< .01](JCMM-22-2935-g003){#jcmm13595-fig-0003}

3.4. Depletion of INPP4B promotes proliferation of CaSki cells {#jcmm13595-sec-0018}
--------------------------------------------------------------

Effect of three INPP4B‐specific siRNA for INPP4B depletion in CaSki cells was measured by Western blot analysis (Figure [4](#jcmm13595-fig-0004){ref-type="fig"}A). We used siINPP4B 1 in following experiments because of its efficient knock‐down of INPP4B expression. In agreement with our findings in other cervical cancer cells, cell proliferation was obviously higher with siINPP4B than control treatment, as detected by CCK‐8 and colony formation assay (Figure [4](#jcmm13595-fig-0004){ref-type="fig"}B and C). More importantly, INPP4B depletion increased the phosphorylation of both AKT (Thr 473) and SGK3 (Thr320) (Figure [4](#jcmm13595-fig-0004){ref-type="fig"}D).

![INPP4B knock‐down promotes proliferation of CaSki cells by elevation of p‐AKT and p‐SGK3. A, Western blot assay of INPP4B in CaSki cells with INPP4B‐specific siRNA (siINPP4Bs) or control siRNA (NC). B, CCK‐8 assay of CaSki cells with siINPP4B1 or NC. \*\**P* \< .01. C, Colony formation assay of CaSki cells with siINPP4B1 or NC. \*\**P* \< .01. Data are mean±SEM, n = 3. D, Western blot assay of AKT and SGK3 in CaSki cells with INPP4B‐specific siRNA (siINPP4Bs) or control siRNA (NC)](JCMM-22-2935-g004){#jcmm13595-fig-0004}

3.5. INPP4B overexpression inhibits tumour growth in vivo {#jcmm13595-sec-0019}
---------------------------------------------------------

To evaluate whether INPP4B suppresses the growth of cervical cancer cells in vivo, we subcutaneously injected HeLa cells stably expressing INPP4B into the armpit of nude mice. Nodules were found in the armpit of mice at 2 weeks after inoculation. At 32 days post‐injection, the tumour size with HeLa‐INPP4B and control injection was 371.3 ± 52.4 vs 121.8 ± 50.46 mm^3^ (Figure [5](#jcmm13595-fig-0005){ref-type="fig"}A, *P* = .0083). The volume and weight of tumours excised were lower with HeLa‐INPP4B than control injection \[volume: 44.00 ± 20.40 vs 150.7 ± 20.02, *P* = .0039; weight: 0.04933 ± 0.01963 vs 0.2107 ± 0.05495, *P* = .02; Figure [5](#jcmm13595-fig-0005){ref-type="fig"}B‐D\]. Consistently, GFP fluorescent signals were more extensive in tumours with control than HeLa‐INPP4B injection (Figure [5](#jcmm13595-fig-0005){ref-type="fig"}E). IHC staining verified the presence of INPP4B in the tumours with HeLa‐INPP4B injection (Figure [5](#jcmm13595-fig-0005){ref-type="fig"}F).

![Overexpression of INPP4B inhibits the growth of cervical cancer cells in mice in vivo. A, Growth curve of xenografts of HeLa cells transfected with GV367‐INPP4B or negative control GV367 in nude mice. Tumour diameters were measured every 4 days. n = 20, \*\**P* \< .01. B‐C, Volume and weight of harvested xenografts of HeLa cells transfected with GV367‐INPP4B or negative control GV367. Data are mean ± SEM, n = 20. \**P* \< .05, \*\**P* \< .01. D, Tumours excised from mice. Top: mice with HeLa control cells, bottom: mice with HeLa‐INPP4B cells. E Fluorescent signals of green fluorescent protein (GFP) in mouse tumours after injection of cells with GV367‐INPP4B or vector GV367. F, Immunohistochemistry staining of fluorescent signals of INPP4B in tumours after injection of cells with GV367‐INPP4B or vector GV367](JCMM-22-2935-g005){#jcmm13595-fig-0005}

3.6. Expression of INPP4B protein in cervical tissues {#jcmm13595-sec-0020}
-----------------------------------------------------

We detected INPP4B in normal and cervical cancer tissues by IHC, with normal skeletal muscle tissues as a positive control (Figure [6](#jcmm13595-fig-0006){ref-type="fig"}A). Among the normal cervical tissues, 20 of 62 squamous cell epithelial samples showed cytoplasmic staining for INPP4B, with a positive rate of 32.3%. No positive staining found in all 6 columnar cell epithelial samples (Figure [6](#jcmm13595-fig-0006){ref-type="fig"}B‐D). Among squamous cell cervical carcinoma samples, 39 of 100 (39%) had positive cytoplasmic INPP4B staining and 61 of 100 (61%) negative staining (Figure [6](#jcmm13595-fig-0006){ref-type="fig"}E and F). For cervical adenocarcinoma samples, 15 of 49 (30.6%) had positive INPP4B staining (also largely in the cytoplasm) and 34 of 49 (69.4%) negative staining (Figure [6](#jcmm13595-fig-0006){ref-type="fig"}G and H). INPP4B protein level did not differ between normal and cancer tissues (*P* = .406) and was not associated with age, clinical stage and other clinicopathological characteristics of patients (*P* \> .05, data not shown). In agreement with IHC findings, in frozen cervical tissues, INPP4B mRNA level did not differ between normal and cervical cancer samples (Figure [6](#jcmm13595-fig-0006){ref-type="fig"}I, *P* = .4108).

![INPP4B protein expression in cervical tissues and cervical cancer cell lines. A, Normal human skeletal muscles, B, normal cervical columnar epithelium (negative), C, normal cervical squamous epithelium (negative), D, normal cervical squamous epithelium (cytoplasm), E, cervical squamous cell carcinoma (negative), F, cervical squamous cell carcinoma (cytoplasm), G, cervical adenocarcinoma (negative), H, cervical adenocarcinoma (cytoplasm) and I, mRNA levels of INPP4B in normal and cervical cancer tissues. Data are mean ± SEM, n = 45. ns, not significant. J, mRNA levels of INPP4B in cervical tissues in Oncomine database](JCMM-22-2935-g006){#jcmm13595-fig-0006}

To verify our results, we referenced the data for INPP4B mRNA expression in the Oncomine database. Two available databases, Biewenga and Scotto Cervix, had similar results as we found (Figure [6](#jcmm13595-fig-0006){ref-type="fig"}J).

4. DISCUSSION {#jcmm13595-sec-0021}
=============

PI3K/AKT is a crucial pathway in carcinogenesis and is deregulated in various tumours including cervical cancer.[8](#jcmm13595-bib-0008){ref-type="ref"}, [18](#jcmm13595-bib-0018){ref-type="ref"}, [19](#jcmm13595-bib-0019){ref-type="ref"} Mutation data from many independent studies showed mutations in PIK3CA and PTEN in various proportions in cervical cancer (13%‐23% in PIK3CA, 5%‐8% in PTEN).[20](#jcmm13595-bib-0020){ref-type="ref"} A recent review found that HPV oncogenes E6/E7/E5 enhance the PI3K/AKT/mTOR signalling pathway by directly activating PI3K and the downstream AKT and p70S6K, which consequently modulates tumour initiation and progression as well as patient outcome in cervical cancer.[21](#jcmm13595-bib-0021){ref-type="ref"} As a negative regulatory molecule of the PI3K/AKT pathway, INPP4B has been reported to have tumour suppression effects in various tumours.[9](#jcmm13595-bib-0009){ref-type="ref"}, [10](#jcmm13595-bib-0010){ref-type="ref"}, [11](#jcmm13595-bib-0011){ref-type="ref"}, [12](#jcmm13595-bib-0012){ref-type="ref"} In our previous study, we found a tumour suppressor protein, LKB1, which inhibits proliferation and up‐regulates the level of INPP4B protein in cervical cancer cells.[16](#jcmm13595-bib-0016){ref-type="ref"} This finding suggests that INPP4B, such as LKB1, may play a suppressive role in cervical cancer. In the present study, we verified that INPP4B impaired cell proliferation, migration and invasive capacity by affecting PI3K/AKT/SGK3 signalling. In addition, INPP4B suppressed tumour growth of xenografted cervical cancer cells in mice.

Our results demonstrated that INPP4B was almost absent in HeLa, SiHa and C33a cells. Ectopic expression of INPP4B inhibited cell proliferation, migration and invasion of cervical cancer cells (Figure [1](#jcmm13595-fig-0001){ref-type="fig"}A‐Figure[2](#jcmm13595-fig-0002){ref-type="fig"}D). Knock‐down of INPP4B in CaSki cells confirmed its suppressive effect on cell proliferation (Figure [4](#jcmm13595-fig-0004){ref-type="fig"}B and C). As well, it obviously impaired the tumour formation of INPP4B‐expressed HeLa cells in a nude mice xenograft model (Figure [5](#jcmm13595-fig-0005){ref-type="fig"}A‐D). In line with those of the previous studies in prostate cancer, basal‐like breast cancer and ovary cancer,[11](#jcmm13595-bib-0011){ref-type="ref"}, [12](#jcmm13595-bib-0012){ref-type="ref"}, [22](#jcmm13595-bib-0022){ref-type="ref"} our results reveal the suppressive role of INPP4B in tumorigenesis of cervical cancer.

The review by Woolley et al[23](#jcmm13595-bib-0023){ref-type="ref"} summarized the mechanism underlying the complexity in function of INPP4B in cancer. Most of the previous studies identified INPP4B as a suppressor of oncogenic growth of cancer cells via the traditional PI3K/INPP4B/AKT axis, whereby INPP4B dephosphorylates PI(3,4)P2 to obstruct the activation of AKT. In agreement, we found that ectopic expression of INPP4B decreased phospho‐AKT and its downstream molecules in cervical cancer cells (Figure [3](#jcmm13595-fig-0003){ref-type="fig"}A). Nevertheless, some recent reports have indicated that INPP4B acts as an oncogenic driver by activating SGK3 in several kinds of cancer cells.[13](#jcmm13595-bib-0013){ref-type="ref"}, [15](#jcmm13595-bib-0015){ref-type="ref"}, [24](#jcmm13595-bib-0024){ref-type="ref"} As a member of a serine/threonine protein kinase family, SGK3 is highly homologous to and shares substrate specificity to the protein kinase B (PKB)/AKT family.[25](#jcmm13595-bib-0025){ref-type="ref"} Tessier et al[25](#jcmm13595-bib-0025){ref-type="ref"} reported that the main product of INPP4B, PI(3)P, can bind to a Phox homology domain of SGK3, thereby targeting the protein to endosomes, where PI3K and PDK1 phosphorylate SGK3 at two regulatory sites (Thr‐320 and Ser‐486). The phosphorylation at the two sites induces the full kinase activity of SGK3. We found that overexpression of INPP4B diminished the activity of SGK3 by decreasing its phosphorylation in cervical cancer cells (Figure [3](#jcmm13595-fig-0003){ref-type="fig"}A). The elevation of p‐SGK3 after INPP4B knock‐down in CaSki cells confirmed this result (Figure [4](#jcmm13595-fig-0004){ref-type="fig"}D). We further found that INPP4B reduced the level of an upstream molecule, PDK1, in the PI3K/AKT pathway (Figure [3](#jcmm13595-fig-0003){ref-type="fig"}B). Considering that PDK1 is one of the important kinases to phosphorylate SGK3, it is reasonable that reduced PDK1 expression resulted in the reduced phosphorylation of SGK3. Our results shed new light on the complex mechanism of the paradoxical function of INPP4B in cancer. In different cancers, INPP4B may affect PI3K/AKT/SGK signal output dissimilarly, which contributes to various biological behaviours in those cancer cells.

In our study, INPP4B expression was lost in the majority of cervical carcinomas, which is consistent with INPP4B as a tumour suppressor (Figure [6](#jcmm13595-fig-0006){ref-type="fig"}). As INPP4B inhibits proliferation of cervical cancer in vitro and in vivo, this protein may serve as a possible candidate for adjuvant therapy of cervical cancer. We also found INPP4B was not detected in a significant number of normal cervical tissues. The low expression of INPP4B in a certain proportion of normal cervix is analogous to that of LKB1, a tumour suppressor upstream of INPP4B, which also displays weak or no expression in normal colorectal, pancreas and cervical tissues.[16](#jcmm13595-bib-0016){ref-type="ref"}, [26](#jcmm13595-bib-0026){ref-type="ref"}, [27](#jcmm13595-bib-0027){ref-type="ref"} We speculate that low expression of INPP4B could be due to lack of tumorigenesis‐associated stresses to INPP4B in normal cervical cells.

Cervical cancer is a pathogenic‐related cancer, with long‐term infection of HPV and interactions between the viral oncoproteins E6/E7 and cellular molecules promoting the transformation of cervical cells. We found that INPP4B inhibited the growth of HPV‐negative cells to a larger extent than that of HPV‐positive cells (Figure [1](#jcmm13595-fig-0001){ref-type="fig"}C‐F). Thus, E6/E7 may be involved in the regulatory role of INPP4B. Overexpression of INPP4B did not changed the level of p53 and Rb protein, two target molecules of E6 and E7, in various cervical cancer cells (data not shown). The mechanism of the crosstalk between INPP4B and HPV E6/E7 needs further investigation.

In summary, we have identified INPP4B as a tumour suppressor in cervical cancer. INPP4B impedes the tumorigenic phenotypes of cervical cancer cells by inhibiting the activation of two downstream molecules of the PI3K pathway, AKT and SGK3. In addition, INPP4B expression significantly prevented tumour growth in mice in vivo. Various inhibitors of molecules in the PI3K/AKT pathway are undergoing pre‐clinical validation for many tumour types.[28](#jcmm13595-bib-0028){ref-type="ref"}, [29](#jcmm13595-bib-0029){ref-type="ref"} INPP4B may also be a potential candidate for adjuvant therapy of cervical cancer and other tumours that are activated in the PI3K pathway.
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